Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer.
Martin H VossMichael S GordonMonica MitaBrian RiniVicky MakkerTeresa MacarullaDavid C SmithAndrés CervantesIgor PuzanovRoberto PiliDing WangShadia JalalShubham PantManish R PatelRachel L NeuwirthAaron EnkeYaping ShouFarhad SedaratiDouglas V FallerHoward A BurrisPublished in: British journal of cancer (2020)
ClinicalTrials.gov, NCT01058707.